Press Releases about Immunovant Inc

Immunovant Inc. (NASDAQ: IMVT) Records 52-Week High Tuesday Morning
September 26, 2023


R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
October 05, 2022
Topics
Death
Exposures
Death

Via NewMediaWire
Topics
Lawsuit

Via NewMediaWire
Topics
Lawsuit

Via NewMediaWire
Topics
Lawsuit


Via NewMediaWire
Topics
Lawsuit

Via NewMediaWire
Topics
Lawsuit

Via NewMediaWire
Topics
Lawsuit
NASDAQ:IMVT Investor Notice: Deadline on April 20, 2021 in Lawsuit Against Immunovant, Inc.
April 07, 2021
Via SBWire
Topics
Lawsuit

Via NewMediaWire
Topics
Lawsuit
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.